



Structural Insights into the Induced-fit Inhibition of Fascin by a Small-Molecule Inhibitor

Jianyun Huang¹, Raja Dey¹, Yufeng Wang¹, Jean Jakoncic², Igor Kurinov³ and Xin-Yun Huang¹

¹ - Department of Physiology and Biophysics, Weill Cornell Medical College of Cornell University, New York, NY 10065, United States

² - Brookhaven National Laboratory, National Synchrotron Light Source, Upton, NY 11973, United States

³ - NE-CAT, Department of Chemistry and Chemical Biology, Cornell University, Lemont, IL 6043, United States

Correspondence to Xin-Yun Huang: xyhuang@med.cornell.edu

<https://doi.org/10.1016/j.jmb.2018.03.009>

Edited by Patrick Griffin

Abstract

Tumor metastasis is responsible for ~90% of all cancer deaths. One of the key steps of tumor metastasis is tumor cell migration and invasion. Filopodia are cell surface extensions that are critical for tumor cell migration. Fascin protein is the main actin-bundling protein in filopodia. Small-molecule fascin inhibitors block tumor cell migration, invasion, and metastasis. Here we present the structural basis for the mechanism of action of these small-molecule fascin inhibitors. X-ray crystal structural analysis of a complex of fascin and a fascin inhibitor shows that binding of the fascin inhibitor to the hydrophobic cleft between the domains 1 and 2 of fascin induces a ~35° rotation of domain 1, leading to the distortion of both the actin-binding sites 1 and 2 on fascin. Furthermore, the crystal structures of an inhibitor alone indicate that the conformations of the small-molecule inhibitors are dynamic. Mutations of the inhibitor-interacting residues decrease the sensitivity of fascin to the inhibitors. Our studies provide structural insights into the molecular mechanism of fascin protein function as well as the action of small-molecule fascin inhibitors.

© 2018 Elsevier Ltd. All rights reserved.

Introduction

Tumor metastasis is the major cause of mortality of cancer patients. Inhibition of tumor metastasis will significantly increase the survival rate of cancer patients. Metastasis is a multi-step process wherein a primary tumor spreads from its initial site to secondary tissues/organs [1–3]. Tumor cell migration and invasion are critical steps in metastasis [4]. Migration provides tumor cells the ability to leave the primary tumor bed (local invasion), enter into blood vessels, and then exit the circulation and infiltrate distant tissues/organs. For cell migration and invasion to proceed, actin cytoskeleton must be reorganized by forming polymers and bundles to cause dynamic changes in cell shapes [5–7]. Among the morphological structures supported by actin filaments, one of the most prominent and best-characterized protrusive organelles is filopodia which are fundamental to cell shape and motility events [8]. Filopodia are finger-like plasma membrane protrusions that are formed upon

remodeling of the actin cytoskeleton beneath the plasma membrane [8]. They can be viewed as a sensory organ of the cells that are used to detect and assimilate signals as well as to explore and move into the surrounding microenvironment [6,8–11]. They contain long-actin filaments crosslinked into parallel bundles by the fascin protein. Metastatic tumor cells are rich in filopodia, and the numbers of filopodia correlate with their invasiveness [6,8,12,13]. Filopodia-like protrusions have also been shown to be critical for metastatic tumor cells to interact with the metastatic microenvironment and to grow at the secondary tissues [14].

Fascin is the main actin cross-linker in filopodia and shows no amino acid sequence homology with other actin-binding proteins [15–20]. It has a molecular mass of ~55 kDa and functions as a monomer [17]. It fastens 10–30 parallel actin filaments together into straight, compact, and rigid bundles, to form filopodia and to impart distinct mechanical stiffness to actin bundles [8,21,22]. When ectopically expressed in tumor cells,

fascin promotes tumor cell migration, invasion, and metastasis [23]. It has also been suggested that up-regulation of fascin is part of the program of epithelial-to-mesenchymal transition that confers motility and invasion properties on tumor cells [24].

Studies on samples from human cancer patients demonstrate that fascin is a biomarker of metastases [25–29]. Elevated levels of fascin have been found in many types of metastatic tumors and are correlated with clinically aggressive phenotypes, poor prognosis, and shorter survival [23,24,30]. Human fascin expression is low or absent in normal adult epithelial cells, but highly expressed in metastatic tumors [31,32]. A systematic review and meta-analysis revealed that high fascin levels are associated with increased risk of mortality, lymph node metastasis, distant metastasis, and disease progression, and may provide a novel biomarker for early identification of aggressive and metastatic tumors [30]. Furthermore, studies from pancreatic cancer patients showed that higher levels of fascin correlate with poor outcome, time to recurrence and decreased overall survival [33]. Taken together, these data from human cancer patients strongly suggest a role for fascin in cancer progression and metastasis.

Mouse genetic studies have shown that fascin gene-knockout mice are normal, likely due to the functional compensation of other actin-bundling proteins during embryonic development [34]. However, deletion of fascin gene delayed tumor development, slowed the tumor growth, reduced metastatic colonization, and increased overall survival in a spontaneous mouse model of pancreatic cancer [33]. Moreover, transgenic expression of fascin in mouse intestinal epithelium increased the tumor incidence, promoted tumor progression, and decreased the overall survival in a spontaneous mouse model of intestinal cancer [35]. These mouse genetic studies provide evidence for fascin in tumor initiation (tumor burden), tumor progression, tumor metastasis, and overall survival.

We screened chemical libraries and identified small-molecule compounds that specifically inhibit the biochemical function of fascin to bundle actin filaments [36]. We optimized one of the initial fascin inhibitor hits and showed that the improved fascin inhibitors block the actin-binding and actin-bundling activities of fascin, tumor cell migration, invasion, and metastasis in mouse models [37]. However, the molecular mechanism of these fascin inhibitors is not clear. In this study, we determined the X-ray crystal structure of fascin complexed with one of these optimized fascin inhibitors, and the X-ray crystal structure of a fascin inhibitor alone. Our results reveal an induced-fit inhibitory mechanism by which a fascin inhibitor causes a major conformational change in fascin leading to the disruption of the actin-binding sites on fascin, thus impairing the actin-bundling function of fascin.

Results

X-ray crystal structure of a complex of fascin and a small-molecule fascin inhibitor

From the chemical library screening for small-molecule compounds that inhibit the actin-bundling function of fascin, we identified several fascin inhibitor hits; one of them was G2 [36] (Fig. 1a). Further medicinal chemical optimization generated improved fascin inhibitors, including NP-G2-029 and NP-G2-044 [37] (Fig. 1b and c). NP-G2-029 inhibited the actin-bundling function of fascin with an IC_{50} value of $\sim 0.18 \mu\text{M}$ (Fig. 1d and e). It also decreased the migration of mouse and human breast tumor cells (Fig. 1f and g).

To understand the structural basis of the inhibition of fascin by NP-G2-029, we solved the X-ray crystal structure of the complex of fascin and NP-G2-029. Fascin has four β -trefoil domains (marked as domains 1–4) [38] (Fig. 2a). From systematic mutagenesis studies of ~ 100 surface residues, amino acids that are critical for actin-bundling are clustered in three regions, named as the possible actin-binding sites 1, 2, and 3 [39] (Fig. 2b). A cryo-electron tomography analysis of the filopodia from intact whole cells proposed that actin-binding sites 1 and 2 interact with two widely positioned two actin monomers on the same F-actin filament, while the actin-binding site 3 interacts with an actin monomer on a second F-actin filament [40]. In the structure of fascin and NP-G2-029, NP-G2-029 binds to a cleft between the domains 1 and 2 (the actin-binding site 2) (Fig. 2c).

The crystals of the complex of fascin and NP-G2-029 diffracted to $\sim 2.8 \text{ \AA}$. The structure was solved by molecular replacement using individual domains of the apo structure of fascin (PDB ID 3LLP) as the search model [38] (Table 1). After initial rounds of rigid body refinement, electron density matching the shape of NP-G2-029 was clearly visible at the actin-binding site 2 (Fig. 2d) and was confirmed by phenix.polder map. In this complex, the benzene ring of NP-G2-029 is surrounded by a number of hydrophobic residues including Phe14, Leu16, Trp101, Leu103, Trp132, and Val134 (Fig. 2e). This benzene ring also forms edge-to-face π - π stacking with Trp101 and Phe14 (Fig. 2e). The planar indazole moiety (formed by the fusion of a pyrazole ring with a benzene ring) constitutes the base plane of NP-G2-029. The benzene ring is oriented $\sim 90^\circ$ with respect to this base plane (Fig. 2f). The backbone of Phe216 forms hydrogen bonds with the pyrazole and the amide of NP-G2-029 (Fig. 2f). In one asymmetric crystallographic unit, there were six fascin and NP-G2-029 molecules; the overall structures of these molecules were similar. The terminal isoxazole ring of NP-G2-029 displayed some flexibility among the six molecules (Fig. 3). This isoxazole ring is in a hydrophilic environment surrounded by Gln11 and Gln50 (Fig. 2f).




Fig. 2. Crystal structure of the complex of fascin and the small-molecule inhibitor NP-G2-029. (a) Crystal structure of wild-type human fascin shows the relative orientation of the four β -trefoil domains (marked by four different colors) of one fascin molecule. (b) Diagram of fascin shows the locations of the three possible actin-binding sites based on the mutagenesis data. (c) X-ray crystal structure of the complex of fascin and NP-G2-029. NP-G2-029 occupies the actin-binding site 2. (d) The electron density map ($2F_o - F_c$ at sigma level of 1.5) for NP-G2-029. (e and f) The binding pocket and some NP-G2-029-interacting residues on fascin are shown.

X-ray crystal structure of a small-molecular fascin inhibitor alone

The NP-G2-029-induced conformational changes on fascin prompted us to investigate the possibility of fascin-induced conformational changes on the small-molecule inhibitors. We set up crystallization screens

for various G2 analogues, and obtained the X-ray crystal structure of the small-molecular fascin inhibitor NP-G2-044 [37] (Fig. 5a and b; Table 2). NP-G2-044 is similar to NP-G2-029 except for a furan ring replaced the isoxazole ring (Fig. 1c). In one asymmetric crystallographic unit, there were two different conformations of NP-G2-044 (Fig. 5a and b). These two

Table 1. Data collection and refinement statistics

	Structure of fascin bound with NP-G2-029 ^a
	Native PDB 6B0T
<i>Data collection</i>	
Space group	<i>P</i> 2
Cell dimensions	
<i>a</i> , <i>b</i> , <i>c</i> (Å)	102.58, 59.25, 293.65
α , β , γ (°)	90, 90.02, 90
Resolution (Å)	45.44–2.8 (2.9–2.8) ^b
No. reflections measured	364,035 (36,079)
No. unique reflections	87,042 (8516)
<i>R</i> _{merge}	0.09 (0.44)
<i>I</i> / σ (<i>I</i>)	13.59 (3.46)
Completeness (%)	99.0 (98.0)
Redundancy	4.2 (4.2)
<i>Refinement</i>	
Resolution (Å)	45.44–2.8
No. reflections (test set)	87,025 (4264)
<i>R</i> _{work} / <i>R</i> _{free} (%)	26.51/30.28
No. non-hydrogen atoms	
Protein	22,818
Ligand	174
Water	344
Mean overall <i>B</i> factor (Å ²)	67.4
Wilson <i>B</i>	38.2
Protein	67.7
Ligand	76.6
Water	43.8
r.m.s. deviations	
Bond lengths (Å)	0.003
Bond angles (°)	0.59
Ramachandran plot statistics ^c (%)	
Favored regions	91.3
Allowed regions	8.1
Disallowed regions	0.6

^a One single crystal was used for data collection and refinement.

^b Values in parentheses are for highest-resolution shell.

^c As defined in MolProbity.

conformations were similar, with the slight orientation difference of the furan ring (Fig. 5c). When compared with the NP-G2-029 structure in the complex with fascin, the benzene ring is rotated by ~180° relative to the planar indazole moiety (Fig. 5d). Given the rotating ability of the benzene ring in relation to the indazole moiety, all these three conformations can be adopted by NP-G2-044 or NP-G2-029 (Fig. 5a–d). Therefore, these small-molecule fascin inhibitors are flexible and sample several different conformations. It is possible that following the binding by a primary conformational selection event, optimization of side-chain interactions proceeds by an induced-fit mechanism to achieve a productive inhibition. Hence, the dynamic conformational ensembles of these inhibitors may play a role in the molecular recognition by fascin.

Biochemical verification of inhibitor-interacting residues

To further experimentally verify the involvement of fascin residues in interacting with NP-G2-029, we

mutated some specific residues and investigated the sensitivity of the mutant fascin proteins to NP-G2-029. In the co-crystal structure of fascin and NP-G2-029, NP-G2-029 forms edge-to-face pi–pi stacking with residues Phe14 and Trp101 (Fig. 5e). We generated the single (Phe14 to Ala, Trp101 to Ala) and the double (Phe14Ala/Trp101Ala) mutations on fascin. These mutant fascin proteins had lower sensitivity to the inhibition by NP-G2-029 (Fig. 5f). Furthermore, in the co-crystal structure of fascin and NP-G2-029, Phe216 forms hydrogen bonds with the pyrazole and the amide of NP-G2-029 (Fig. 5e). Ile93 forms hydrophobic interaction with the fused benzene ring of the indazole moiety of NP-G2-029 (Fig. 5e). We made the single (Ile93 to Ala, Phe216 to Ala) and the double (Ile93Ala/Phe216Ala) mutants, and observed reduced sensitivity of these mutated fascin proteins to the inhibition by NP-G2-029 (Fig. 5f). Moreover, these mutated fascin proteins had decreased sensitivity to the inhibition by NP-G2-044 as well (Fig. 5f). Together, these biochemical data support the participation of these residues in the inhibition of fascin by NP-G2-029 and NP-G2-044.

Discussion

In an effort to elucidate the structural basis by which the small-molecule fascin inhibitors block the biological function of fascin, we solved the X-ray crystal structure of a complex of fascin and a small-molecule fascin inhibitor. In the structure of fascin and NP-G2-029, NP-G2-029 binds to a cleft between the domains 1 and 2 (the actin-binding site 2) of fascin. This structure of the complex also reveals that the N-terminal of fascin is critical for coupling the two actin-binding sites and for binding to NP-G2-029. Furthermore, our data indicate that the small-molecule fascin inhibitors are flexible and can adopt different conformations. This dynamics of the inhibitors might be important for the induced-fit inhibition process. Moreover, several amino acid residues on fascin participating in the interaction with the inhibitor were confirmed by mutation studies.

From the co-crystal structure of the complex of fascin and NP-G2-029, the trifluoromethyl (-CF₃) group and the benzene ring of NP-G2-029 are deeply embedded into fascin. These two groups are likely the main contributors to the binding of NP-G2-029 and its analogs to fascin. This is consistent with our structure–activity relationship studies that most modifications in these positions abolished the capability of the compounds to inhibit the actin-bundling activity of fascin [37]. Furthermore, the isoxazole ring of NP-G2-029 showed some flexibility among the six NP-G2-029 molecules in the structure of the complex. This also agrees with our structure–activity relationship studies that this part of the small-molecule inhibitors could be extensively modified to fine-tune the efficacy of the inhibitors.




Fig. 3. Electron density maps of the six NP-G2-029 molecules in one asymmetric crystallographic unit of the complex of fascin and NP-G2-029. $2F_o - F_c$ maps are shown. NP-G2-029 is shown at 1-sigma level and the side chains of nearby amino acid residues are displayed at 1.5-sigma level.

Moreover, the NP-G2-029 binding site on fascin is formed upon the binding of NP-G2-029. In the absence of NP-G2-029, the actin-binding site 2 is fully enclosed. The rotation of the domain 1 opens up a hydrophobic and tight pocket for the binding of the $-CF_3$ and benzene ring of NP-G2-029. This rotation results in the widening of the actin-binding site 2 and the closing of the actin-binding site 1, leading to the inhibition of the actin-bundling activity of fascin. Our data also explain that, although we started by screening chemical libraries for protein–protein interaction inhibitors, we obtained small-molecule inhibitors capable of binding to fascin in the absence of actin proteins.

Our structural data provide a mechanistic explanation for the cooperativity among the actin-binding sites. It has been shown that the actin-binding activity of fascin is cooperative [42]. Our data reveal that the N-terminal of fascin connects the actin-binding sites 1 and 2, and that conformational changes in one actin-binding site could lead to a concerted conformational change on the other actin-binding site. Hence, it is likely that binding of one F-actin filament at one actin-binding site stabilizes fascin at the active configuration and enhances the binding of actin at the other actin-binding sites. It is also possible that mutations of residues in the actin-binding site 1 could affect the small-molecule inhibitor binding to the actin-binding site 2 [36,37]. Furthermore, the unexpected flexibility

of domain 1 might have implications for the role of fascin protein in the flexibility of the bundled fascin-actin filaments as well as of filopodia. Filopodia are highly dynamic cellular protrusions. They scan the local environment by turning, elongation, and retraction. These require filopodia to be flexible enough to wave about, yet rigid enough to protrude the cell surface. Previous structural studies showed that the conformations of wild-type active fascin protein and four inactive fascin mutants were similar with minor local structural variations, implying that the configuration of fascin is rather rigid [38,39,43,44]. Our current structural data reveal that the domain 1 could be rotated; this might underlie the flexibility of the fascin/actin bundles and of filopodia. Therefore, our results might provide insights on the roles of fascin in the stability, dynamics, and organizations of filopodia in cells. The dynamic structures of fascin and the small-molecule inhibitors offer the opportunity and the challenge in generating the next-generation of fascin inhibitors for clinical uses.

Materials and Methods

Chemistry

Compound syntheses and analyses were done by the company ValueTek Inc. (NJ, USA). All reagents

and solvents were purchased from Sigma-Aldrich Chemical Co., Combi-Block Inc., Astatech Inc., Ark Pharma Inc., and Frontier Scientific Inc. and were used

as received. HNMR spectra were recorded on a Bruker Fourier-400 spectrometer. Crude products were purified by silica gel chromatography. For all products, the




Fig. 4 (legend on next page)

purity was ascertained to be greater than 95% by the HPLC method using Shimadzu 2010HPLC-UV/MS system with a C-18 reverse phase column.

General procedures for **NP-G2-029** and **NP-G2-044**: A mixture of KOH (6.95 g, 124 mmol) in DMSO (165 mL) was stirred at room temperature for 5 min. 1H-indazol-3-amine (8.25 g, 62.0 mmol) was then added in one portion. The resulting mixture was stirred at room temperature for 5 min. A solution of 4-trifluoromethylbenzyl bromide (15.6 g, 65.1 mmol) in DMSO (83 mL) was then added dropwise over 30 min. When the addition was complete, the resulting mixture was stirred at room temperature for an additional 1 h. The mixture was quenched by the addition of water (200 mL). The mixture was then extracted with CH₂Cl₂ (3 × 100 mL). The combined extracts were washed with H₂O (2 × 100 mL), brine (1 × 100 mL), then dried over MgSO₄, filtered and concentrated *in vacuo*. Purification by flash chromatography (Silica, 200 g, 10–100% EtOAc/hexanes) gave 1-(trifluoromethylbenzyl)-1H-indazol-3-amine (21.79 g, 56.6 mmol, 91.3% yield) as an off-white crystalline solid. Mass spectrometry (electrospray ionization; MS (ESI)] *m/z*: 292 (M + H)⁺. To a solution of 1-(trifluoromethylbenzyl)-1H-indazol-3-amine (29.2 mg, 0.10 mmol), furan-2-carboxylic acid (12.3 mg, 0.11 mmol), and triethylamine (45.2 μL, 0.30 mmol) in dichloromethane (2 mL) was added 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (118.6 μL, 0.20 mmol). The resulting reaction mixture was stirred at room temperature for 3 h and then the solvent was removed. The crude product was purified by preparative HPLC (sunfire 5u 100-mm column, MeOH/H₂O as solvents). *N*-(1-(4-(trifluoromethyl)benzyl)-1H-indazol-3-yl)furan-2-carboxamide (compound **G2**) of 23 mg (0.0597 mmol, 59.7%) was obtained as an off-white solid. ¹H NMR (400 MHz, chloroform-*d*) δ 8.73 (s, 1H), 8.18 (d, *J* = 8.2 Hz, 1H), 7.50–7.59 (m, 3H), 7.35–7.43 (m, 1H), 7.24–7.33 (m, 4H), 7.17 (ddd, *J* = 0.88, 6.99, 8.20 Hz, 1H), 6.58 (dd, *J* = 1.76, 3.52 Hz, 1H), 5.54 (s, 2H). MS (ESI) calcd for C₂₀H₁₄F₃N₃O₂ (M + H)⁺ *m/z* 386.10, found 386.12.

Compound **NP-G2-029**: 4-methyl-*N*-(1-(4-(trifluoromethyl)benzyl)-1H-indazol-3-yl)isoxazole-5-carboxamide (compound **NP-G2-029**) was prepared as described for the preparation of compound **G2** with replacement of furan-2-carboxylic acid with 4-methylisoxazole-5-carboxylic acid in 63.1% yield as an off-white solid. ¹H NMR (400 MHz, chloroform-*d*) δ 8.85 (s, 1H), 8.28 (s, 1H), 8.14 (d, *J* = 8.25 Hz, 1H),

7.59 (d, *J* = 7.98 Hz, 2H), 7.43 (s, 1H), 7.33–7.38 (m, 3H), 7.23 (t, *J* = 7.57 Hz, 1H), 5.56 (s, 2H), 2.47 (s, 3H). MS (ESI) calcd for C₂₀H₁₅F₃N₄O₂ (M + H)⁺ *m/z* 401.11, found 401.11.

Compound **NP-G2-044**: 2-methyl-*N*-(1-(4-(trifluoromethyl)benzyl)-1H-indazol-3-yl)furan-3-carboxamide (compound **NP-G2-044**) was prepared as described for the preparation of compound **G2** with replacement of furan-2-carboxylic acid with 2-methylfuran-3-carboxylic acid in 79.6% yield as an off-white solid. ¹H NMR (400 MHz, chloroform-*d*) δ 8.05–8.16 (m, 2H), 7.54 (d, *J* = 8.14 Hz, 2H), 7.36–7.43 (m, 1H), 7.31 (d, *J* = 1.98 Hz, 1H), 7.28 (d, *J* = 0.66 Hz, 2H), 7.26 (s, 1H), 7.18 (ddd, *J* = 0.88, 6.99, 8.20 Hz, 1H), 6.60 (d, *J* = 1.98 Hz, 1H), 5.53 (s, 2H), 2.87 (s, 3H). MS (ESI) calcd for C₂₁H₁₆F₃N₃O₂ (M + H)⁺ *m/z* 400.12, found 400.12.

Cell culture

Mouse 4T1 mammary tumor cells and human MDA-MB-231 breast cancer cells were obtained from American Type Culture Collection. 4T1 cells and MDA-MB-231 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum as previously described [36–38].

Human fascin-1 expression and purification

Recombinant human fascin 1 was expressed as a glutathione *S*-transferase fusion protein in BL21 *Escherichia coli*. 1-l of 2YT medium with ampicillin was inoculated overnight with 3 mL of BL21/DE3 culture transformed with pGEX4T-fascin 1 plasmid and grown at 37 °C until attenuation at 600 nm (OD₆₀₀) reached about 0.5. The culture was then transferred to 17 °C and induced by the addition of 0.1 mM IPTG for 16 h. Bacteria were harvested by centrifugation at 5000 r.p.m. for 10 min. The pellets were suspended in 30 mL of Tris/HCl [20 mM Tris/HCl (pH 8.0), 150 mM NaCl] supplemented with 0.2 mM PMSF, 1 mM DTT, 1% Triton X-100, and 1 mM EDTA. After sonication, the suspension was centrifuged at 15,000 r.p.m. for 30 min to remove the cell debris. The supernatant was then incubated for 2 h with 4 mL of glutathione beads (Sigma) at 4 °C. After extensive washing with Tris/HCl [20 mM Tris/HCl (pH 8.0), 150 mM NaCl], the beads were resuspended in 10 mL of thrombin cleavage buffer [20 mM Tris–HCl (pH 8.0), 150 mM NaCl, 2 mM CaCl₂, 1 mM DTT]. Fascin was released from the

Fig. 4. NP-G2-029 induced changes in fascin conformation. (a) Structure of the actin-binding site 2 in the absence of NP-G2-029. (b) Structure of the actin-binding site 2 with bound NP-G2-029. (c) Superposition of fascin structures in the absence or presence of NP-G2-029. The color marking of the four domains of fascin in the presence of NP-G2-029 is the same as in Fig. 2c. The structure of fascin in the absence of NP-G2-029 is colored in light blue. Relative to the location in the absence of NP-G2-029, domain 1 rotated ~35 Å clockwise in the presence of NP-G2-029. (d) The rotating axle of domain 1 is marked by a rod. (e) The N-terminal (marked in red) of fascin couples the actin-binding sites 1 and 2. (f) The N-terminal of fascin participates in the binding of NP-G2-029.




Fig. 5. Fascin induces a conformational change on the small-molecule inhibitor. (a) X-ray crystal structure of one conformation of NP-G2-044. (b) X-ray crystal structure of the second conformation of NP-G2-044. (c) Superposition of the two conformations of NP-G2-044. (d) Superposition of one conformation of NP-G2-044 and the NP-G2-029 structure when it is bound to fascin. (e) Diagram shows the positions of Phe14, Trp101, Ile93, and Phe216 residues which are involved in the inhibitor binding. (f) Summary of the actin-bundling data of wild-type and mutant fascin proteins in the presence of various concentrations of NP-G2-029 or NP-G2-044. The IC₅₀ values are the mean of three repeats. Data are expressed as mean ± SD and analyzed by Student's *t* test with significance defined as $p < 0.05$. * marks the mutants, when compared with the wild-type, with $p < 0.05$.

beads by incubation overnight with 40–100 U of thrombin at 4 °C. After centrifugation, 0.2 mM PMSF was added to the supernatant to inactivate the remnant thrombin activity. The fascin protein was further concentrated with Centricon to about 50 mg/mL.

F-actin-bundling assay

Actin-bundling activity was measured by low-speed centrifugation assay. Monomeric rabbit G-actin was induced to polymerize at room temperature in F-actin

Table 2. Small-molecule NP-G2-044 X-ray data collection and refinement

Empirical formula	C42 H34 F6 N6 O5
Formula weight	816.75
Temperature	100(2) K
Wavelength	0.97915 (Å)
Crystal system	Monoclinic
Space group	C2/c
Unit cell dimensions	
<i>a</i> , <i>b</i> , <i>c</i> (Å)	35.240(7), 12.290(2), 19.970(4)
α , β , γ (°)	90.00, 118.13, 90.00
Volume	7627.4(3) (Å ³)
Z	8
Density (calculated)	1.423
Absorption coefficient	0.40 mm ⁻¹
<i>F</i> (000)	3376
Crystal size	0.10, 0.05, 0.04 mm ³
Theta range for data collection	1.81–30.32 (°)
Resolution range	15.5–1.0 Å
Index range	–34 ≤ <i>h</i> ≤ 34, –12 ≤ <i>k</i> ≤ 11, –20 ≤ <i>l</i> ≤ 19
Reflections collected	12,379
Independent reflections	3792
Completeness to theta max = 30.32°	86.4%
Absorption correction	Empirical
Refinement method	Full-matrix least-squares on <i>F</i> ²
Data/restraints/parameters	3792/477/543
Goodness-of-fit on <i>F</i> ²	1.202
Final <i>R</i> indices [<i>I</i> > 2sigma(<i>I</i>)]	<i>R</i> 1 = 0.0464, <i>wR</i> 2 = 0.1212
<i>R</i> indices (all data)	<i>R</i> 1 = 0.0478, <i>wR</i> 2 = 0.1224
Largest diff. peak and hole	0.30 and –0.35 e.Å ⁻³

buffer (20 mM Tris–HCl at pH 8, 1 mM ATP, 1 mM DTT, 2 mM MgCl₂, and 100 mM KCl). Recombinant fascin proteins (wide-type or mutant) were subsequently incubated with F-actin for 30 min at room temperature and centrifuged for 15 min at 10,000*g* in an Eppendorf 5415D tabletop centrifuge. Both supernatants and pellets were dissolved in an equivalent volume of SDS sample buffer, and the amount of fascin was determined by SDS-PAGE. We measured the intensities of fascin proteins in Coomassie-stained gels and then calculated the relative actin-bundling activity.

Boyden-chamber cell migration assay

MDA-MB-231 cells (5 × 10⁴) suspended in 100 μL starvation medium were added to the upper chamber of an insert (6.5-mm diameter, 8-μm pore size; Becton Dickson), and the insert was placed in a 24-well plate containing 700 μL starvation medium with or without 10% fetal bovine serum. When used, inhibitors were added to both the upper and the lower chambers. Migration assays were performed for 6 h and cells were fixed with 3.7% formaldehyde. Cells were stained with crystal violet staining solution, and cells on the upper side of the insert were removed with a cotton swab. Three randomly selected fields (10 objectives) on the lower side of the insert were photographed, and the migrated cells were counted. Migration was expressed as a migration index (number of migrating cells treated

with a fascin inhibitor divided by the number of migrating cells left untreated).

Crystallization of the complex of fascin and NP-G2-029

The concentrated fascin protein stock solution was diluted with the buffer [20 mM Tris (pH 8.0), 40 mM KBr, 0.5 mM EDTA, 1 mM DTT] to 15 mg/mL prior crystallization. The final concentration of the small-molecule inhibitors was 2 mM. The mixture was incubated at room temperature for 1 h. Crystallization was performed by the vapor diffusion hanging drop method at 18 °C. The complex was crystallized in 100 mM Hepes (pH 7.5), 20% polyethylene glycol (PEG) 4000, and 2.5% isopropanol. Crystals were briefly transferred to the cryo-solution which consisted of the crystallization solution implemented with 15% glycerol and flash-cooled in liquid nitrogen.

Data collection, structure determination, and refinement

Diffraction data were collected at 100 K using synchrotron radiation ($\lambda = 1.3$ Å) at the beamline X6A, National Synchrotron Light Source (Brookhaven, USA). The data reduction was performed with XDS, followed by merging and scaling with XSCALE [45]. The corresponding data-collection statistics are shown in Table 1, created by PHENIX (1.10.1-2155). Searching by individual β -trefoil fold of fascin (PDB 3LLP) gave the solution using PHASER molecular replacement program (version 2.5.7) in CCP4 suite (version 6.5.016) [46]. Model building, refinement, and analysis were carried out using COOT (version 0.8.5) and PHENIX (1.10.1–2155) based on σ -A weighted $2F_o - F_c$ and $F_o - F_c$ maps, as well as non-crystallographic symmetry averaged and unaveraged maps [47,48]. The slightly high *R* values might be due to the tight stereochemical restraints. The model was verified with simulated annealing omit map created in PHENIX. Refinement statistics are also presented in Table 1, and the stereochemical quality of the refined structures was validated using MolProbity [49]. Graphical representations of structures were prepared using PyMol (DeLano Scientific, San Francisco, CA, USA). Solvent molecules were identified from the difference Fourier map ($F_o - F_c$) above sigma level of 3. Six molecules per asymmetric unit have been observed with clear electron density for the small molecules at the actin-binding site 2.

Crystallization and data processing of NP-G2-044

Very thin plate-like crystals of NP-G2-044 were grown at 18 °C by hanging drop method with the well solution of 24% PEG4000, 0.1 M Hepes (pH 7.5), and 2.5% isopropanol. Compound NP-G2-044 was dissolved in 25% PEG400, 25% PEG 4000, 0.1 M

Hepes (pH 7.5), and 2.5% isopropanol with final concentration of 4 mM. Drops were set at 1:1 ratio of well and compound solution. X-ray diffraction data for thin plate-like crystal of NP-G2-044 to 1-Å resolution were collected at 100 K using synchrotron radiation ($\lambda = 0.9792$ Å) at NE-CAT 24ID-C beamline at APS, Argonne, using Pilatus 6 M-F detector. The data were reduced using XDS. Crystals belong to the space group *C2/c* with cell dimensions $a = 35.25$ Å, $b = 12.29$ Å, $c = 19.97$ Å, and $\beta = 118.13$. Two molecules were observed in the asymmetric unit with opposite orientation of the furan ring with respect to the central indazole moiety.

Accession codes

The atomic coordinates and structure factors for the complex of fascin and NP-G2-029 have been deposited in the Protein Data Bank under accession number 6B0T. The structure of NP-G2-044 is deposited in the Cambridge Crystallographic Data Centre (<http://www.ccdc.cam.ac.uk/>) under accession number 1576496.

Acknowledgments

We thank C. Shue, G. Wu, and J. Zhang for assistance with the project, and C. Hu, G. Wu, J. Zhang, and S. Zheng for comments on the structures and the manuscript. This work was supported by a Sponsored Research Agreement from Novita Pharmaceuticals to Weill Cornell Medical College and by a National Institutes of Health (NIH) grant CA193815. Part of this work is based on research conducted at the Northeastern Collaborative Access Team beamlines, which are funded by the NIGMS from the NIH (P41 GM103403). The Pilatus 6M detector on 24-ID-C beam line is funded by an NIH-ORIP HEI grant (S10 RR029205). This research used resources of the Advanced Photon Source, a US Department of Energy Office of Science User Facility operated for the Department of Energy Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357.

Competing Financial Interests: X.Y.H. is a co-founder and has equity in Novita Pharmaceuticals. The remaining authors declare no competing financial interests.

Received 5 December 2017;

Received in revised form 7 February 2018;

Accepted 8 March 2018

Available online 21 March 2018

Keywords:
crystal structure;
fascin;
actin cytoskeleton;
small-molecule inhibitor

Abbreviations used:

PEG, polyethylene glycol; MS (ESI), mass spectrometry (electrospray ionization).

References

- [1] L. Weiss, Metastasis of cancer: a conceptual history from antiquity to the 1990s, *Cancer Metastasis Rev.* 19 (I-XI) (2000) 193–383.
- [2] I.J. Fidler, The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited, *Nat. Rev. Cancer* 3 (2003) 453–458.
- [3] S. Valastyan, R.A. Weinberg, Tumor metastasis: molecular insights and evolving paradigms, *Cell* 147 (2011) 275–292.
- [4] J. Condeelis, R.H. Singer, J.E. Segall, The great escape: when cancer cells hijack the genes for chemotaxis and motility, *Annu. Rev. Cell Dev. Biol.* 21 (2005) 695–718.
- [5] A.B. Jaffe, A. Hall, Rho GTPases: biochemistry and biology, *Annu. Rev. Cell Dev. Biol.* 21 (2005) 247–269.
- [6] A. Mogilner, B. Rubinstein, The physics of filopodial protrusion, *Biophys. J.* 89 (2005) 782–795.
- [7] T.D. Pollard, J.A. Cooper, Actin, a central player in cell shape and movement, *Science* 326 (2009) 1208–1212.
- [8] P.K. Mattila, P. Lappalainen, Filopodia: molecular architecture and cellular functions, *Nat. Rev. Mol. Cell Biol.* 9 (2008) 446–454.
- [9] R.W. Davenport, P. Dou, V. Rehder, S.B. Kater, A sensory role for neuronal growth cone filopodia, *Nature* 361 (1993) 721–724.
- [10] D. Bentley, A. Toroian-Raymond, Disoriented pathfinding by pioneer neurone growth cones deprived of filopodia by cytochalasin treatment, *Nature* 323 (1986) 712–715.
- [11] T.A. Sanders, E. Llagostera, M. Barna, Specialized filopodia direct long-range transport of SHH during vertebrate tissue patterning, *Nature* 497 (2013) 628–632.
- [12] P.J. Coopman, M.T. Do, E.W. Thompson, S.C. Mueller, Phagocytosis of cross-linked gelatin matrix by human breast carcinoma cells correlates with their invasive capacity, *Clin. Cancer Res.* 4 (1998) 507–515.
- [13] W. Wang, J.B. Wyckoff, V.C. Frohlich, Y. Oleynikov, S. Huttelmaier, J. Zavadil, et al., Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling, *Cancer Res.* 62 (2002) 6278–6288.
- [14] T. Shibue, M.W. Brooks, M.F. Inan, F. Reinhardt, R.A. Weinberg, The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions, *Cancer Discov.* 2 (2012) 706–721.
- [15] J.J. Otto, R.E. Kane, J. Bryan, Formation of filopodia in coelomocytes: localization of fascin, a 58,000 dalton actin cross-linking protein, *Cell* 17 (1979) 285–293.
- [16] J. Bryan, R.E. Kane, Separation and interaction of the major components of sea urchin actin gel, *J. Mol. Biol.* 125 (1978) 207–224.
- [17] S. Yamashiro-Matsumura, Matsumura F. Purification, characterization of an F-actin-bundling 55-kilodalton protein from HeLa cells, *J. Biol. Chem.* 260 (1985) 5087–5097.

- [18] D. Vignjevic, D. Yarar, M.D. Welch, J. Peloquin, T. Svitkina, G.G. Borisy, Formation of filopodia-like bundles in vitro from a dendritic network, *J. Cell Biol.* 160 (2003) 951–962.
- [19] D. Vignjevic, S. Kojima, Y. Aratyn, O. Danciu, T. Svitkina, G. G. Borisy, Role of fascin in filopodial protrusion, *J. Cell Biol.* 174 (2006) 863–875.
- [20] J.C. Adams, Roles of fascin in cell adhesion and motility, *Curr. Opin. Cell Biol.* 16 (2004) 590–596.
- [21] L.G. Tilney, P.S. Connelly, K.A. Vranich, M.K. Shaw, G.M. Guild, Why are two different cross-linkers necessary for actin bundle formation in vivo and what does each cross-link contribute? *J. Cell Biol.* 143 (1998) 121–133.
- [22] M.M. Claessens, M. Bathe, E. Frey, A.R. Bausch, Actin-binding proteins sensitively mediate F-actin bundle stiffness, *Nat. Mater.* 5 (2006) 748–753.
- [23] Y. Hashimoto, D.J. Kim, J.C. Adams, The roles of fascins in health and disease, *J. Pathol.* 224 (2011) 289–300.
- [24] L.M. Machesky, A. Li, Fascin: invasive filopodia promoting metastasis, *Commun. Integr. Biol.* 3 (2010) 263–270.
- [25] A.D. Darnel, E. Behmoaram, R.T. Vollmer, J. Corcos, K. Bijian, K. Sircar, et al., Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer, *Clin. Cancer Res.* 15 (2009) 1376–1383.
- [26] G. Pelosi, F. Pasini, F. Frassetto, U. Pastorino, A. Iannucci, P. Maisonneuve, et al., Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids, *Lung Cancer* 42 (2003) 203–213.
- [27] Y. Hashimoto, Y. Shimada, J. Kawamura, S. Yamasaki, M. Imamura, The prognostic relevance of fascin expression in human gastric carcinoma, *Oncology* 67 (2004) 262–270.
- [28] D. Cao, H. Ji, B.M. Ronnett, Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary, *Int. J. Gynecol. Pathol.* 24 (2005) 67–72.
- [29] S.M. Rodríguez-Pinilla, D. Sarrio, E. Honrado, D. Hardisson, F. Calero, J. Benitez, et al., Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas, *Clin. Cancer Res.* 12 (2006) 1533–1539.
- [30] V.Y. Tan, S.J. Lewis, J.C. Adams, R.M. Martin, Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis, *BMC Med.* 11 (2013) 52.
- [31] A. Grothey, R. Hashizume, A.A. Sahin, McCrea PD, Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer, *Br. J. Cancer* 83 (2000) 870–873.
- [32] Y. Hashimoto, M. Skacel, J.C. Adams, Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? *Int. J. Biochem. Cell Biol.* 37 (2005) 1787–1804.
- [33] A. Li, J.P. Morton, Y. Ma, S.A. Karim, Y. Zhou, W.J. Faller, et al., Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes, *Gastroenterology* 146 (2014) (1386-96 e1-17).
- [34] Y. Yamakita, F. Matsumura, S. Yamashiro, Fascin1 is dispensable for mouse development but is favorable for neonatal survival, *Cell Motil. Cytoskeleton* 66 (2009) 524–534.
- [35] M. Schoumacher, F. El-Marjou, M. Lae, N. Kambou, D. Louvard, S. Robine, et al., Conditional expression of fascin increases tumor progression in a mouse model of intestinal cancer, *Eur. J. Cell Biol.* 93 (2014) 388–395.
- [36] F.K. Huang, S. Han, B. Xing, J. Huang, B. Liu, F. Bordeleau, et al., Targeted inhibition of fascin function blocks tumour invasion and metastatic colonization, *Nat. Commun.* 6 (2015) 7465.
- [37] S. Han, J. Huang, B. Liu, B. Xing, F. Bordeleau, C.A. Reinhart-King, et al., Improving fascin inhibitors to block tumor cell migration and metastasis, *Mol. Oncol.* 10 (2016) 966–980.
- [38] L. Chen, S. Yang, J. Jakoncic, J.J. Zhang, X.Y. Huang, Migrastatin analogues target fascin to block tumour metastasis, *Nature* 464 (2010) 1062–1066.
- [39] S. Yang, F.K. Huang, J. Huang, S. Chen, J. Jakoncic, A. Leo-Macias, et al., Molecular mechanism of fascin function in filopodial formation, *J. Biol. Chem.* 288 (2013) 274–284.
- [40] S. Aramaki, K. Mayanagi, M. Jin, K. Aoyama, T. Yasunaga, Filopodia formation by crosslinking of F-actin with fascin in two different binding manners, *Cytoskeleton (Hoboken)* 73 (2016) 365–374.
- [41] S. Ono, Y. Yamakita, S. Yamashiro, P.T. Matsudaira, J.R. Gnarr, T. Obinata, et al., Identification of an actin binding region and a protein kinase C phosphorylation site on human fascin, *J. Biol. Chem.* 272 (1997) 2527–2533.
- [42] Y. Yamakita, S. Ono, F. Matsumura, S. Yamashiro, Phosphorylation of human fascin inhibits its actin binding and bundling activities, *J. Biol. Chem.* 271 (1996) 12632–12638.
- [43] R.S. Sedeh, A.A. Fedorov, E.V. Fedorov, S. Ono, F. Matsumura, S.C. Almo, et al., Structure, evolutionary conservation, and conformational dynamics of *Homo sapiens* fascin-1, an F-actin crosslinking protein, *J. Mol. Biol.* 400 (2010) 589–604.
- [44] S. Jansen, A. Collins, C. Yang, G. Rebowski, T. Svitkina, R. Dominguez, Mechanism of actin filament bundling by fascin, *J. Biol. Chem.* 286 (2011) 30087–30096.
- [45] W. Kabsch, Xds, *Acta Crystallogr. D Biol. Crystallogr.* 66 (2010) 125–132.
- [46] A.J. McCoy, R.W. Grosse-Kunstleve, P.D. Adams, M.D. Winn, L.C. Storoni, R.J. Read, Phaser crystallographic software, *J. Appl. Crystallogr.* 40 (2007) 658–674.
- [47] G.N. Murshudov, A.A. Vagin, E.J. Dodson, Refinement of macromolecular structures by the maximum-likelihood method, *Acta Crystallogr. D Biol. Crystallogr.* 53 (1997) 240–255.
- [48] P. Emsley, K. Cowtan, Coot: model-building tools for molecular graphics, *Acta Crystallogr. D Biol. Crystallogr.* 60 (2004) 2126–2132.
- [49] I.W. Davis, L.W. Murray, J.S. Richardson, D.C. Richardson, MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes, *Nucleic Acids Res.* 32 (2004) W615–9.